Your session is about to expire
← Back to Search
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
N/A
Waitlist Available
Led By Matthew Davenport, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
The purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (Eovist) or intravenous gadobenate dimeglumine (MultiHance).
Eligible Conditions
- Liver Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Survey
Secondary study objectives
Oxygen Levels
Respiratory Rate
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Patients having MRI with MultihanceExperimental Treatment1 Intervention
Subjects having a clinically ordered MRI with Multihance. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the scan. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
Group II: Patients having MRI with EovistExperimental Treatment1 Intervention
Subjects having a clinically ordered MRI with Eovist. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the can. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gadobenic acid
FDA approved
Gadoxetic acid
FDA approved
Find a Location
Who is running the clinical trial?
University of MichiganLead Sponsor
1,863 Previous Clinical Trials
6,441,424 Total Patients Enrolled
2 Trials studying Liver Cancer
5,617 Patients Enrolled for Liver Cancer
Matthew Davenport, MDPrincipal InvestigatorUniversity of Michigan Hospital
1 Previous Clinical Trials
1 Total Patients Enrolled